TX-MARY-KAY
15.2.2024 18:14:28 CET | Business Wire | Press release
Since 2021, Mary Kay Inc. has partnered with the Equal Rights Trust (ERT), an organization whose mission is to advance equality through law around the world. As part of this collaboration, Mary Kay Inc. supported new research focused on understanding and addressing the discriminatory impacts of artificial intelligence (AI) and its impacts on gender equality, and the development of a new “equality by design approach.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240215911706/en/
“Our collaboration with Equal Rights Trust underscores our dedication to ensuring that technological advancements, especially in AI, champion gender equality. The impact of the Principles on Equality by Design in Algorithmic Decision-Making has already been transformative for key stakeholders in AI and echoes our commitment to helping create an inclusive digital economy where women entrepreneurs can excel without bias or barriers,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. (Photo: Mary Kay Inc.)
The initiative culminated with the recent launch of a new set of legal standards – the Principles on Equality by Design in Algorithmic Decision-Making – developed by the Equal Rights Trust and endorsed by a group of leading international equality organizations. The Principles elaborate why national governments and businesses must adopt such an approach and provide detailed guidance for its implementation.
Jim Fitzgerald, Director of Equal Rights Trust, just released an article highlighting the rapid advancements and transformative potential of artificial intelligence while also warning about adverse impacts and discriminatory threats unregulated algorithmic systems could pose.
- Read Jim Fitzgerald’s article titled Equality by Design: A Model for Managing Discriminatory Risks of AI here.
Statements from Jim Fitzgerald, Director of Equal Rights Trust and Melinda Foster Sellers, Chief People Officer at Mary Kay Inc., can be found below:
- “Over the last three years, Mary Kay has supported our research, analysis, and consultation on algorithmic discrimination, and enabled us to develop the Principles on Equality by Design,” said Jim Fitzgerald, Director of the Equal Rights Trust. “Now, Mary Kay is working with us as we move into the next phase: a collaborative effort to develop practical guidance for business on how to adopt the equality by design approach. In doing so, it is taking the next step in a journey which started with strong internal equality and non-discrimination policies, moved to collaboration with and support for us and other actors in this field, and is now focused on incubating and piloting best practice. In this journey, Mary Kay is helping to model how businesses can play an active role in developing improved approaches to eliminating discrimination and advancing equality.”
- "At Mary Kay, we recognize the profound impact that AI has on shaping the future of business and society,” said Melinda Foster Sellers, Chief People Officer at Mary Kay Inc. “Our collaboration with Equal Rights Trust underscores our dedication to ensuring that technological advancements, especially in AI, champion gender equality. The impact of the Principles on Equality by Design in Algorithmic Decision-Making has already been transformative for key stakeholders in AI and echoes our commitment to helping create an inclusive digital economy where women entrepreneurs can excel without bias or barriers. This partnership reflects our enduring mission to empower women and promote equality in every sphere."
About Equal Rights Trust
The Equal Rights Trust is an independent international non-governmental organization which exists to eliminate discrimination and ensure everyone can participate in society on an equal basis. To achieve this, it works in partnership to provide expert support to those on the frontlines of the fight against discrimination, enabling them to press for the development, adoption, and implementation of equality law, and to use the law effectively. Since 2007, the Trust has supported equality activists in more than 50 countries, while developing consensus at the international level on the need for and content of comprehensive equality laws. Learn more at equalrightstrust.org
About Mary Kay
Then. Now. Always. One of the original glass ceiling breakers, Mary Kay Ash founded her dream beauty brand in Texas in 1963 with one goal: to enrich women’s lives. That dream has blossomed into a global company with millions of independent sales force members in more than 35 countries. For 60 years, the Mary Kay opportunity has empowered women to define their own futures through education, mentorship, advocacy, and innovation. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skincare, color cosmetics, nutritional supplements, and fragrances. Mary Kay believes in preserving our planet for future generations, protecting women impacted by cancer and domestic abuse, and encouraging youth to follow their dreams. Learn more at marykayglobal.com. Find us on Facebook, Instagram, and LinkedIn, or follow us on X (formerly known as Twitter)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240215911706/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Netceed Strengthens Board with Global Infrastructure and Technology Leaders1.4.2026 14:00:00 CEST | Press release
Netceed, a global leader in delivering supply chain solutions across broadband, data center and energy infrastructure, today announced the appointment of Franck Bruel, Jan Frykhammar and Stacey Thompson to advise as strategic advisors to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260401045867/en/ Franck Bruel Following the recently announced recapitalization of the Netceed Group and under the chairmanship of Rajeev Suri, the company is strengthening its Board with globally recognized leaders across telecommunications infrastructure, industrial distribution, energy infrastructure and hyperscale technology. Collectively, the new appointees bring decades of leadership experience across some of the world’s most influential infrastructure and technology companies, reflecting Netceed’s ambition to play a leading role in the next generation of global digital, AI and energy infrastructure. Rajeev Suri, Ch
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States1.4.2026 13:30:00 CEST | Press release
-With this expansion, any variant that results in production of CFTR protein is now included in the indication for ALYFTREK and TRIKAFTA, reinforcing the impact these medicines have, regardless of the location of the variant in the CFTR protein--Approximately 800 more people with CF in the US are now eligible for a CFTR modulator for the first time- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 6 and older with a variant in the cystic fibrosis transmembrane conductance regulator (CFTR) gene that is either responsive based on clinical and/or in vitro data or results in production of CFTR protein. Additionally, the U.S. FDA has also expanded the indication statement for TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in patients ages 2 and older. This label expansion was supported b
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer1.4.2026 13:30:00 CEST | Press release
A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer CasesColorectal Cancer Has Become the Leading Cause of Cancer-related Death in Adults Under Age 50 Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global phase 3 BATTMAN (CO.33) trial (NCT07152821). This study is evaluating Agenus’ immunotherapy combination of botensilimab (BOT) plus balstilimab (BAL) versus best supportive care in patients with refractory, unresectable microsatellite stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC), a population long considered resistant to immunotherapy. This study is being conducted as a cooperative group trial led by the Canadian Cancer Trials Group (CCTG) from Canada and run across Canada, France, Australia and New Zealand. More than 100 sites will participate across the academic cooper
Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release
Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user
Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release
Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom